SYGNIS Signs Non-exclusive Distribution Agreement with Cambridge Bioscience
News May 05, 2015
SYGNIS AG has announced a distribution agreement with Cambridge Bioscience for the commercialization of SYGNIS’ proprietary product portfolio in the UK and Ireland. Since the Department for Business, Innovation & Skills, the UK life science industry is one of the world leaders with more than 4,000 companies, employing around 160,000 people and with a total annual turnover of over £50 billion.
Under the terms of the agreement, Cambridge Bioscience will promote, market, sell and support TruePrime™ products for primer-free WGA as well as SunScript™ thermostable reverse transcriptase kits for the translation of RNA into DNA to researchers in molecular biology in the UK and Ireland.
TruePrime™ is based on SYGNIS’ revolutionary novel multiple displacement amplification (MDA) technology addressing key challenges in NGS applications, increasingly demanded in fields such as oncology, pathology and clinical diagnostics.
SYGNIS’ SunScript™ product line covers a series of kits based on novel proprietary engineered reverse transcriptase (RT) which today is one of the most thermostable and fastest enzymes commercially available. RTs are commonly used in molecular biology to convert genetic information from RNA molecules back to DNA, enabling a number of downstream analyses of RNA molecules using DNA analysis methods such as NGS or polymerase chain reaction (PCR) in gene expression profiling and molecular diagnostics.
Cambridge Bioscience is a leading UK based distributor of cutting-edge life science research products including a broad portfolio of innovative products and technologies for molecular biology applications such as NGS, epigenetics, gene regulation, cloning, DNA extraction and purification, amplification, quantification, delivery as well as high-end instrumentation.
“We are very pleased to announce the distribution agreement for an strategically important European key market such as the UK which in addition also represents one of the biggest life science industries worldwide,” Pilar de la Huerta, CEO and CFO of SYGNIS commented. “Cambridge Bioscience complements our fast growing list of leading international distribution partners and proves the ongoing interest and demand in our proprietary product and technology family.”
Measuring Neutrophil Motility Could Lead to Accurate Sepsis DiagnosisNews
Mass. General researchers design device that rapidly diagnoses sepsis with more than 95 percent accuracy.READ MORE
Largest Genetic Study of Osteoarthritis Advances ResearchNews
Osteoarthritis is a complex disease, and the genetic basis of the disease has proved difficult to pin down. A new study from the Sanger Institute provides much-needed hope.READ MORE
Comments | 0 ADD COMMENT
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
World Congress on Advances in Addiction Science and Medicine
Sep 24 - Sep 25, 2018